展示双特异性 T 细胞衔接器的工程化细胞外囊泡用于 B 细胞恶性肿瘤的靶向治疗

Engineered extracellular vesicles displaying bi-specific T-cell engagers for targeted therapy of B-cell malignancies.

CAR-T 细胞治疗后免疫效应细胞相关神经毒性综合征：最新进展综述

Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances.

ICANS 的管理正转向精准医学模式。

胞啃作用在肿瘤与免疫交叉点：机制、意义与治疗前景

Trogocytosis at the crossroad of cancer and immunity: mechanisms, implications and therapeutic perspectives.

通过内吞途径切换和干扰素反应抑制增强工程化细胞外囊泡的抗肿瘤效应

Enhancing Anti-Tumor Effects of Engineered Extracellular Vesicles via Endocytosis Route Switching and Interferon Response Suppression.

通过利用 CAR 靶点修饰的细胞外囊泡的靶向细胞因子递送系统改善 CAR-T 细胞功能

Improving CAR-T cell function through a targeted cytokine delivery system utilizing car target-modified extracellular vesicles.

淋巴瘤来源细胞外囊泡抑制 CAR-T 细胞功能

Lymphoma-derived extracellular vesicles inhibit CAR T cell function.

CD19.CAR-T 细胞来源的细胞外囊泡表达 CAR 并杀伤白血病细胞，参与抗肿瘤治疗

CD19.CAR T-cell-derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy.

聚焦外泌体以突破 CAR-T 细胞治疗的现有瓶颈

Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy.

CAR+ 细胞外囊泡预测接受靶向 CD19 的 CAR-T 细胞治疗的 B 细胞淋巴瘤患者的 ICANS

CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells.

肿瘤来源外泌体通过外泌体 CD19 抗原诱导初始活化，但经 TGF-β 信号通路损害 CD19 特异性 CAR-T 细胞功能

Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling.